5G and Future Networks

Cell, Molecule and Material Interaction is an essential component in the development of the next generation therapies including Advanced Therapy Medicinal Products (ATMPs). Our capabilities cover core discovery techniques utilising both primary derived human and animal cells as well as immortalised cell lines in static and flow bioreactors. We utilise primary, terminally differentiated and progenitor cell sources to evaluate biocompatibility. MTIF is able to develop in vitro platforms such as 3D tissue analogues, enabling the development of cellular models using tissue-on-a-chip, Clustered Regularly Interspaced Short Palindromic Repeats – associated protein-9 nuclease (CRISPR/Cas9) or combinations of both approaches. We are able to fully characterise materials including testing to IS010993.